Santhera Pharmaceuticals Holding Valuation
Is SANN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SANN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SANN (CHF11.44) is trading below our estimate of fair value (CHF644.59)
Significantly Below Fair Value: SANN is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SANN?
Key metric: As SANN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is SANN's PE Ratio? | |
|---|---|
| PE Ratio | 2.2x |
| Earnings | CHF 62.86m |
| Market Cap | CHF 138.49m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | 2.6x |
| PEG Ratio | 0.06x |
Price to Earnings Ratio vs Peers
How does SANN's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 59.8x | ||
CGEN Compugen | 91.3x | -59.8% | US$143.3m |
XLS Xlife Sciences | 7x | n/a | CHF 148.1m |
1875 TOT BIOPHARM International | 141x | n/a | HK$1.2b |
OBSN ObsEva | 0.02x | n/a | CHF 140.6k |
SANN Santhera Pharmaceuticals Holding | 2.2x | 35.4% | CHF 138.5m |
Price-To-Earnings vs Peers: SANN is good value based on its Price-To-Earnings Ratio (2.2x) compared to the peer average (57x).
Price to Earnings Ratio vs Industry
How does SANN's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Earnings vs Industry: SANN is good value based on its Price-To-Earnings Ratio (2.2x) compared to the European Biotechs industry average (26.9x).
Price to Earnings Ratio vs Fair Ratio
What is SANN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 2.2x |
| Fair PE Ratio | 19.7x |
Price-To-Earnings vs Fair Ratio: SANN is good value based on its Price-To-Earnings Ratio (2.2x) compared to the estimated Fair Price-To-Earnings Ratio (19.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CHF 11.44 | CHF 32.00 +179.7% | 21.9% | CHF 39.00 | CHF 25.00 | n/a | 2 |
| Dec ’25 | CHF 8.20 | CHF 32.00 +290.2% | 21.9% | CHF 39.00 | CHF 25.00 | n/a | 2 |
| Nov ’25 | CHF 8.77 | CHF 32.00 +264.9% | 21.9% | CHF 39.00 | CHF 25.00 | n/a | 2 |
| Oct ’25 | CHF 9.17 | CHF 32.00 +249.0% | 21.9% | CHF 39.00 | CHF 25.00 | n/a | 2 |
| Sep ’25 | CHF 9.00 | CHF 34.50 +283.3% | 13.0% | CHF 39.00 | CHF 30.00 | n/a | 2 |
| Aug ’25 | CHF 9.29 | CHF 34.50 +271.4% | 13.0% | CHF 39.00 | CHF 30.00 | n/a | 2 |
| Jul ’25 | CHF 8.51 | CHF 34.50 +305.4% | 13.0% | CHF 39.00 | CHF 30.00 | n/a | 2 |
| Jan ’25 | CHF 9.81 | CHF 71.00 +623.8% | 57.7% | CHF 112.00 | CHF 30.00 | n/a | 2 |
| Dec ’24 | CHF 9.59 | CHF 70.00 +629.9% | 60.0% | CHF 112.00 | CHF 28.00 | CHF 8.20 | 2 |
| Nov ’24 | CHF 10.82 | CHF 70.00 +547.0% | 60.0% | CHF 112.00 | CHF 28.00 | CHF 8.77 | 2 |
| Oct ’24 | CHF 8.34 | CHF 68.00 +715.3% | 64.7% | CHF 112.00 | CHF 24.00 | CHF 9.17 | 2 |
| Sep ’24 | CHF 8.64 | CHF 68.00 +687.0% | 64.7% | CHF 112.00 | CHF 24.00 | CHF 9.00 | 2 |
| Aug ’24 | CHF 8.59 | CHF 68.00 +691.6% | 64.7% | CHF 112.00 | CHF 24.00 | CHF 9.29 | 2 |
| Feb ’24 | CHF 8.79 | CHF 88.00 +901.1% | 54.5% | CHF 136.00 | CHF 40.00 | CHF 9.35 | 2 |
| Jan ’24 | CHF 13.80 | CHF 88.00 +537.7% | 54.5% | CHF 136.00 | CHF 40.00 | CHF 9.81 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 08:24 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Santhera Pharmaceuticals Holding AG is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maurizio Bernasconi | Bank am Bellevue |
| Silvia Schanz | Bank Vontobel AG |
| Barbora Blaha | Credit Suisse |